Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCD | O00767 | 9/20 | 0.57 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.43 |
| ▸ | NAMPT | P43490 | 2/20 | 0.43 |
| ▸ | MLYCD | O95822 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | DCTPP1 | Q9H773 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2295558 | 0.96 | SCD (0.59) | SCDDCTPP1 | |
| SCHEMBL2294056 | 0.92 | SCD (0.61) | SCDDCTPP1 | |
| SCHEMBL2299671 | 0.89 | SCD (0.62) | SCDDCTPP1 | |
| SCHEMBL8083811 | 0.87 | SCD (0.63) | SCDDCTPP1 | |
| SCHEMBL5312052 | 0.84 | SCD (0.59) | SCDALDH1A1HPGDSMN1; SMN2DCTPP1 | |
| SCHEMBL8101715 | 0.84 | SCD (0.53) | SCDDCTPP1 | |
| SCHEMBL2299343 | 0.83 | SCD (0.81) | SCDNAMPTALDH1A1HPGDSMN1; SMN2 | |
| SCHEMBL2293937 | 0.83 | SCD (0.81) | SCDNAMPTDCTPP1 | |
| SCHEMBL2294104 | 0.81 | SCD (0.55) | SCDALDH1A1HPGDSMN1; SMN2DCTPP1 | |
| SCHEMBL2294174 | 0.81 | SCD (0.55) | SCDDCTPP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110245263-A1 | 2-HETEROARYL-PYRROLO[3,4-C]PYRROLE DERIVATIVES AND THEIR USE AS SCD | SANOFI-AVENTIS (FR) | 2011-10-06 | — | — | US | claimed |
| US-20100144594-A1 | 2-HETEROARYL-PYRROLO[3,4-C]PYRROLE DERIVATIVES AND THEIR USE AS SCD INHIBITORS | SANOFI-AVENTIS (FR) | 2010-06-10 | — | — | US | claimed |
| US-9358250-B2 | Methods of using SCD1 antagonists | GENENTECH, INC. (US) | 2016-06-07 | — | — | US | disclosed |
| US-9358250-B2 | Methods of using SCD1 antagonists | GENENTECH, INC. (US) | 2016-06-07 | — | — | US | disclosed |
| US-20130096181-A1 | METHODS OF USING SCD1 ANTAGONISTS | GENENTECH, INC. (US) | 2013-04-18 | — | — | US | disclosed |
| US-20130096181-A1 | METHODS OF USING SCD1 ANTAGONISTS | GENENTECH, INC. (US) | 2013-04-18 | — | — | US | disclosed |
| US-20110245263-A1 | 2-HETEROARYL-PYRROLO[3,4-C]PYRROLE DERIVATIVES AND THEIR USE AS SCD | SANOFI-AVENTIS (FR) | 2011-10-06 | — | — | US | disclosed |
| US-20110245263-A1 | 2-HETEROARYL-PYRROLO[3,4-C]PYRROLE DERIVATIVES AND THEIR USE AS SCD | SANOFI-AVENTIS (FR) | 2011-10-06 | — | — | US | disclosed |
| US-8003677-B2 | 2-heteroaryl-pyrrolo[3,4-c]pyrrole derivatives and their use as SCD inhibitors | SANOFI-AVENTIS (FR) | 2011-08-23 | — | — | US | disclosed |
| US-8003677-B2 | 2-heteroaryl-pyrrolo[3,4-c]pyrrole derivatives and their use as SCD inhibitors | SANOFI-AVENTIS (FR) | 2011-08-23 | — | — | US | disclosed |
| EP-2152711-B1 | 2 -HETEROARYL- PYRROLO [3, 4-C]PYRROLE DERIVATIVES AND THEIR USE AS SCD INHIBITORS | SANOFI AVENTIS (FR) | 2010-11-24 | — | — | EP | disclosed |
| US-20100144594-A1 | 2-HETEROARYL-PYRROLO[3,4-C]PYRROLE DERIVATIVES AND THEIR USE AS SCD INHIBITORS | SANOFI-AVENTIS (FR) | 2010-06-10 | — | — | US | disclosed |
| US-20100144594-A1 | 2-HETEROARYL-PYRROLO[3,4-C]PYRROLE DERIVATIVES AND THEIR USE AS SCD INHIBITORS | SANOFI-AVENTIS (FR) | 2010-06-10 | — | — | US | disclosed |
| EP-2152711-A1 | 2 -HETEROARYL- PYRROLO [3, 4-C]PYRROLE DERIVATIVES AND THEIR USE AS SCD INHIBITORS | Sanofi-Aventis (FR) | 2010-02-17 | — | — | EP | disclosed |
| WO-2008135141-A1 | 2 -HETEROARYL- PYRROLO [3, 4-C] PYRROLE DERIVATIVES AND THEIR USE AS SCD INHIBITORS | SANOFI-AVENTIS (FR) | 2008-11-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100144594-A1 | 2-HETEROARYL-PYRROLO[3,4-C]PYRROLE DERIVATIVES AND THEIR USE AS SCD INHIBITORS | SCD, SCD5, PYCR1 | SCD 1/4885HDAC6 4669/4885NAMPT 1406/4885 |
| US-20130096181-A1 | METHODS OF USING SCD1 ANTAGONISTS | SCD, SELPLG, SCD5 | SCD 1/4885HDAC6 3932/4885NAMPT 458/4885 |
| US-20110245263-A1 | 2-HETEROARYL-PYRROLO[3,4-C]PYRROLE DERIVATIVES AND THEIR USE AS SCD | SCD, SCD5, PYCR1 | SCD 1/4885HDAC6 4638/4885NAMPT 1694/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.